Prevalence of TMC278 (rilpivirine) associated mutations in the Frankfurt Resistance DatabaseREINHEIMER, Claudia; DOERR, Hans W; STURMER, Martin et al.Journal of clinical virology. 2012, Vol 53, Num 3, pp 248-250, issn 1386-6532, 3 p.Article

Genotypic and Phenotypic Characterization of HIV-1 Isolates Obtained From Patients on Rilpivirine Therapy Experiencing Virologic Failure in the Phase 3 ECHO and THRIVE Studies: 48-Week AnalysisRIMSKY, Laurence; VINGERHOETS, Johan; VAN EYGEN, Veerle et al.Journal of acquired immune deficiency syndromes (1999). 2012, Vol 59, Num 1, pp 39-46, issn 1525-4135, 8 p.Article

Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infectionNICOT, F; SALIOU, A; RAYMOND, S et al.Journal of clinical virology. 2012, Vol 55, Num 2, pp 107-113, issn 1386-6532, 7 p.Article

Stratégies thérapeutiques antirétrovirales non conventionnelles en première ligne du traitement de l'infection par le VIH-1 = Toward new strategies for first-line antiretroviral treatment of HIV-1 infected patientsDELAUGERRE, Constance; GHOSN, Jade.Virologie (Montrouge). 2012, Vol 16, Num 6, pp 371-380, issn 1267-8694, 10 p.Article

Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological responseVINGERHOETS, Johan; RIMSKY, Laurence; VAN EYGEN, Veerle et al.Antiviral therapy (London). 2013, Vol 18, Num 2, pp 253-256, issn 1359-6535, 4 p.Article

Lack of Pharmacokinetic Interaction between Rilpivirine and Integrase Inhibitors Dolutegravir and GSK1265744FORD, Susan L; GOULD, Elizabeth; SHUGUANG CHEN et al.Antimicrobial agents and chemotherapy. 2013, Vol 57, Num 11, pp 5472-5477, issn 0066-4804, 6 p.Article

Rilpivirine Inhibits Drug Transporters ABCB1, SLC22A1, and SLC22A2 In VitroMOSS, Darren M; LIPTROTT, Neill J; CURLEY, Paul et al.Antimicrobial agents and chemotherapy. 2013, Vol 57, Num 11, pp 5612-5618, issn 0066-4804, 7 p.Article

Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baselineASAHCHOP, Eugene L; WAINBERG, Mark A; OLIVEIRA, Maureen et al.AIDS (London). 2013, Vol 27, Num 6, pp 879-887, issn 0269-9370, 9 p.Article

Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatmentBAERT, Lieven; VAN 'T KLOOSTER, Gerben; VAN REMOORTERE, Pieter et al.European journal of pharmaceutics and biopharmaceutics. 2009, Vol 72, Num 3, pp 502-508, issn 0939-6411, 7 p.Article

Lack of an effect of rilpivirine on the pharmacokinetics of ethinylestradiol and norethindrone in healthy volunteersCRAUWELS, Herta M; VAN HEESWIJK, Rolf P. G; BUELENS, Annemie et al.International journal of clinical pharmacology and therapeutics. 2014, Vol 52, Num 2, pp 118-128, issn 0946-1965, 11 p.Article

Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1-Infected Patients: Pooled Results From the Phase 3 Double-Blind Randomized ECHO and THRIVE TrialsCOHEN, Calvin J; MOLINA, Jean-Michel; CRAUWELS, Herta et al.Journal of acquired immune deficiency syndromes (1999). 2012, Vol 60, Num 1, pp 33-42, issn 1525-4135, 10 p.Article

The HIV-1 Reverse Transcriptase MI841 Mutation Enhances the E138K-Associated Resistance to Rilpivirine and Decreases Viral FitnessKULKARNI, Rima; BABAOGLU, Kerim; LANSDON, Eric B et al.Journal of acquired immune deficiency syndromes (1999). 2012, Vol 59, Num 1, pp 47-54, issn 1525-4135, 8 p.Article

Human Biotransformation of the Nonnucleoside Reverse Transcriptase Inhibitor Rilpivirine and a Cross-Species Metabolism ComparisonLADE, Julie M; AVERY, Lindsay B; BUMPUS, Namandjé N et al.Antimicrobial agents and chemotherapy. 2013, Vol 57, Num 10, pp 5067-5079, issn 0066-4804, 13 p.Article

96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trialsRIMSKY, Laurence; VAN EYGEN, Veerle; HOOGSTOEL, Annemie et al.Antiviral therapy (London). 2013, Vol 18, Num 8, pp 967-977, issn 1359-6535, 11 p.Article

Long-Term Efficacy, Safety, and Tolerability of Rilpivirine (RPV, TMC278) in HIV Type 1-Infected Antiretroviral-Naive Patients: Week 192 Results from a Phase llb Randomized TrialWILKIN, Aimee; POZNIAK, Anton L; MORALES-RAMIREZ, Javier et al.AIDS research and human retroviruses. 2012, Vol 28, Num 5, pp 437-446, issn 0889-2229, 10 p.Article

Pharmacokinetics and Disposition of Rilpivirine (TMC278) Nanosuspension as a Long-Acting Injectable Antiretroviral FormulationVAN 'T KLOOSTER, Gerben; HOEBEN, Eva; BORGHYS, Herman et al.Antimicrobial agents and chemotherapy. 2010, Vol 54, Num 5, pp 2042-2050, issn 0066-4804, 9 p.Article

E138A in HIV-1 reverse transcriptase is more common in subtype C than B: Implications for rilpivirine use in resource-limited settingsSLUIS-CREMER, Nicolas; JORDAN, Michael R; HUBER, Kelly et al.Antiviral research. 2014, Vol 107, pp 31-34, issn 0166-3542, 4 p.Article

E138K and M1841 mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposureFOURATI, Slim; MALET, Isabelle; CALVEZ, Vincent et al.AIDS (London). 2012, Vol 26, Num 13, pp 1619-1624, issn 0269-9370, 6 p.Article

Nonnucleoside Reverse Transcriptase Inhibitor Resistance and the Role of the Second-Generation AgentsADAMS, Jessica; PATEL, Nimish; MANKARYOUS, Nancy et al.The Annals of pharmacotherapy. 2010, Vol 44, Num 1, pp 157-165, issn 1060-0280, 9 p.Article

Effects of Rilpivirine on Human Adipocyte Differentiation, Gene Expression, and Release of Adipokines and CytokinesDIAZ-DELFFIN, Julieta; DOMINGO, Pere; MATEO, Maria Gracia et al.Antimicrobial agents and chemotherapy. 2012, Vol 56, Num 6, pp 3369-3375, issn 0066-4804, 7 p.Article

Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compoundsELSE, Laura; WATSON, Victoria; TJIA, John et al.Journal of chromatography. B. 2010, Vol 878, Num 19, pp 1455-1465, issn 1570-0232, 11 p.Article

Naturally Selected Rilpivirine-Resistant HIV-1 Variants by Host Cellular ImmunityGATANAGA, Hiroyuki; MURAKOSHI, Hayato; HACHIYA, Atsuko et al.Clinical infectious diseases. 2013, Vol 57, Num 7, pp 1051-1055, issn 1058-4838, 5 p.Article

Dead-end complexes contribute to the synergistic inhibition of HIV-1 RT by the combination of rilpivirine, emtricitabine, and tenofovirKULKARNI, Rima; FENG, Joy Y; MILLER, Michael D et al.Antiviral research. 2014, Vol 101, pp 131-135, issn 0166-3542, 5 p.Article

Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 years (1989-2009)DE BETHUNE, Marie-Pierre.Antiviral research. 2010, Vol 85, Num 1, pp 75-90, issn 0166-3542, 16 p.Article

Résistance aux nouveaux antirétroviraux = HIV-1 resistance to new antiretroviral drugsDELAUGERRE, Constance.La Lettre de l'infectiologue. 2008, Vol 23, Num 5, pp 169-174, issn 0296-9009, 6 p.Article